Wang, S.-J.; Chen, H.-H.; Sun, L.; Shih, Y.-H.; Lu, T.-F.; Chen, Y.-F.; Fan, C.-T.; Hsu, S.-T.; Liu, C.-K.; Hwang, S.-F.;
et al. Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel. J. Clin. Med. 2024, 13, 5670.
https://doi.org/10.3390/jcm13195670
AMA Style
Wang S-J, Chen H-H, Sun L, Shih Y-H, Lu T-F, Chen Y-F, Fan C-T, Hsu S-T, Liu C-K, Hwang S-F,
et al. Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel. Journal of Clinical Medicine. 2024; 13(19):5670.
https://doi.org/10.3390/jcm13195670
Chicago/Turabian Style
Wang, Shao-Jing, Hsin-Hua Chen, Lou Sun, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Chun-Ting Fan, Shih-Tien Hsu, Chin-Ku Liu, Sheau-Feng Hwang,
and et al. 2024. "Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel" Journal of Clinical Medicine 13, no. 19: 5670.
https://doi.org/10.3390/jcm13195670
APA Style
Wang, S.-J., Chen, H.-H., Sun, L., Shih, Y.-H., Lu, T.-F., Chen, Y.-F., Fan, C.-T., Hsu, S.-T., Liu, C.-K., Hwang, S.-F., & Lu, C.-H.
(2024). Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel. Journal of Clinical Medicine, 13(19), 5670.
https://doi.org/10.3390/jcm13195670
